Trials / Completed
CompletedNCT01044914
Genes, Intermediate Phenotypes and Response to Quetiapine RX
Use of Clinical and Intermediate Phenotypes to Assess Response to Quetiapine: the Role of Putative Causative Genes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- University of Bari · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Pharmacological treatment of schizophrenia is still characterized by a certain proportion of patients who are resistant to common antipsychotics. Variability in individual response ranges from patients who experience complete or near complete symptom remission to a subset of patients who remain treatment-refractory despite extensive drug trials over years. The investigators propose to take advantage of the simultaneous acquisition of clinical and of intermediate phenotypes to ascertain the possible contribution of SNPs within putative causative genes to response to treatment with quetiapine XR.
Conditions
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2010-01-08
- Last updated
- 2016-05-13
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01044914. Inclusion in this directory is not an endorsement.